Physician profile
Supriya Koya
NPI 1770790289
$7,388.59
in general payments reported to CMS, 2019-2025
58 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $19.85 · 2021: $1,044 · 2022: $1,820 · 2023: $1,889 · 2024: $1,054 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.06 |
| Education | $771.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $842.52 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $778.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $738.48 | 2021-2025 | |
| Seagen INC. | $366.95 | 2021-2023 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $357.71 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $264.00 | 2021-2025 | Keytruda, Lynparza |
| Amgen INC. | $233.79 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Lilly USA, LLC | $214.76 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $204.00 | 2021-2024 | Opdivo |
| Gilead Sciences, INC. | $183.55 | 2021-2025 | Trodelvy |
| Celgene Corporation | $178.90 | 2022-2023 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $176.44 | 2021-2023 | |
| Genentech USA, INC. | $155.89 | 2022-2024 | Phesgo, Itovebi, Polivy |
| Pharmacyclics LLC, An Abbvie Company | $152.28 | 2021-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $140.01 | 2021-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Koya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.